{
  "links": "https://www.ycombinator.com/companies/general-proximity",
  "name": "General Proximity",
  "headline": "The next generation of induced-proximity medicines.",
  "batch": "W20",
  "description": null,
  "activity_status": "Active",
  "website": "https://www.generalproximity.bio/",
  "founded_date": null,
  "team_size": 15.0,
  "location": "San Francisco",
  "group_partner": "Jared Friedman",
  "group_partner_yc": "https://www.ycombinator.com/people/jared-friedman",
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:biotech; industry:drug-discovery; location:san-francisco-bay-area",
  "founders": [
    {
      "name": "Armand Cognetta, Founder",
      "description": "Armand completed his PhD in Chemical Biology at the Scripps Research Institute under the supervision of Dr. Benjamin F. Cravatt. There he co-authored 19 scientific publications in prestigious journals such as Cell, Nature, and Science, as well as multiple patents, including a portion of the foundational IP for Abide Therapeutics (acq. Lundbeck) and Vividion Therapeutics (acq. Bayer). Prior to founding GP he was an early employee at the Flagship Pioneering start-up Inzen Tx (now Sonata).",
      "linkedin": "https://www.linkedin.com/in/armandcognetta/"
    }
  ],
  "status": true,
  "markdown": "raw_markdown=\"[![General Proximity Logo](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6761c0d619a9810afc4ed7d2_gplogo.svg)](https://www.generalproximity.bio/</>)\\n  * [Team](https://www.generalproximity.bio/</team>)\\n  * [Careers](https://www.generalproximity.bio/</careers>)\\n  * [News](https://www.generalproximity.bio/</news>)\\n\\n\\n![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67609cf8935161e8a93a2a78_hero-img.avif)\\n# Nothing\\nWe’re pioneering next-gen proximity medicines to redefine the future of medicine for all humankind.\\n# is\\n# Undruggable\\nWe’re pioneering next-gen proximity medicines to redefine the future of medicine for all humankind.\\n## Control Proximity,Control Biology\\nFirst Principles: All biological processes are driven by proximity. Why don’t our medicines work in the same way?\\n### general\\n[jen-rəl]\\nadjective\\nApplicable to all, unbiased\\nWe’ve built the first generalized, mechanism-agnostic, proximity discovery engine.Our genomes code for thousands of intricate molecular machines—effector proteins—which regulate all aspects of biology. These include chaperone, adaptor proteins, and trafficking proteins, all post-translational modification (PTM) readers/writers/erasers, and many others.In aggregate, these effector proteins comprise the ‘effectome’: the set of all proteins which modulate other proteins to control biology.To us they represent something even more: a boundless array of untapped biological tools.\\u200d\\n### proximity\\n[präk-si-mə-tē]\\nnoun\\nCloseness\\nProximity is a master regulator of biology. All biological processes are controlled through proximity on some level.Interactions or ‘proximity events’ between ‘target’ and ‘effector proteins’ can result in a vast constellation of downstream biology on a target protein—activation, refolding, re-localization, re-programming, functional modulation, degradation, etc. Manipulation of a given protein’s proximity topology thus enables nearly arbitrary control of that protein's function and biology.Our unbiased effector discovery platform allows us to discover the most powerful proximity mechanisms for a given target, enabling the development of highly-efficacious proximity therapeutics for targets previously beyond the reach of medicine.\\u200d\\u200d\\n[Play](https://www.generalproximity.bio/<#>)[Pause](https://www.generalproximity.bio/<#>)\\nCollaborating with world-class institutions to create next gen proximity medicines\\n[![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/676062518843c91f8458f2d8_jlabs.png)J&J](https://www.generalproximity.bio/<https:/www.jnj.com/>)[![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f627dc9a3bad1b99d67_image%202685.avif)UCSF](https://www.generalproximity.bio/<https:/www.ucsf.edu/>)[![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/675a168d71b65c4bf3dc103c_moffitt-logo-full-white.svg)Moffitt Cancer Center](https://www.generalproximity.bio/<https:/www.moffitt.org/>)[![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f614da550fde650a759_elogo.avif)JLabs](https://www.generalproximity.bio/<https:/enamine.net/>)\\nBacked by leading technical investors\\n[Healthspan Capital![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f61995a0ea29ffc262c_image%202697.avif)](https://www.generalproximity.bio/<https:/www.healthspancapital.vc/>)[Wilson Sonsini![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f61d21f02b787f474a2_Wilson_Sonsini_Logo%201.avif)](https://www.generalproximity.bio/<https:/www.wsgr.com/en/services/practice-areas/corporate/emerging-companies.html>)[![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f62f992eb0d2d7c55fc_age1logo.avif)Age1](https://www.generalproximity.bio/<https:/age1.com/>)[Felisis Ventures![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f62388a8321634e1c87_Frame%201538233611.avif)](https://www.generalproximity.bio/<https:/www.felicis.com/>)[Olive Capital![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f627623048bcd522dc2_image%202692%20\\\\(Traced\\\\).avif)](https://www.generalproximity.bio/<https:/www.olivevc.com/>)[![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f6280b07605dbfd034a_image%202691.avif)Modi Ventures](https://www.generalproximity.bio/<https:/www.modivc.com/>)[![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f62c3e594b815519642_ycombinator-icon%201.avif)Y Combinator](https://www.generalproximity.bio/<https:/www.ycombinator.com/>)\\nSupported by major grants\\n[ARPA H![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6761b9be747e99faf31bc418_ARPA-H.svg)](https://www.generalproximity.bio/<https:/www.linkedin.com/feed/update/urn:li:activity:7255651295984771072/>)[NCI![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6761bb7a85cd8c690946748e_NIH%20NCI.svg)](https://www.generalproximity.bio/<https:/www.cancer.gov/>)\\n[![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5f7d9edf61c7e54560_MBC-Biolabs-logo%20161.avif)MBC Biolabs](https://www.generalproximity.bio/<https:/mbcbiolabs.com/>)\\nAwarded a record number of big pharma “Golden Tickets”\\n[Servier![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5f318f6d1da69fbb0b_servierlogo.avif)](https://www.generalproximity.bio/<https:/servier.com/en/servier/>)[Astellas![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5f6165b3f1a3914936_logo_white%201.avif)](https://www.generalproximity.bio/<https:/www.astellas.com/en/>)[Bristol Meyers Squib![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5f02963a4bfacaac70_Vector.png)](https://www.generalproximity.bio/<https:/www.bms.com/>)[Abbvie![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5fa650bf84c47baad9_AbbVie_logo%201.avif)](https://www.generalproximity.bio/<https:/www.abbvie.com/>)[Ono Pharma![Company Logo\\n](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6744a44686918e9eeec3ac4c_onologo.svg)](https://www.generalproximity.bio/<https:/www.ono-pharma.com/en>)\\n## Our team is responsible for:\\n36+\\nFDA Approved Medicines\\n146\\nINDs\\n245\\nPatents\\n958\\nPublications\\n[our team](https://www.generalproximity.bio/<#>)[our team](https://www.generalproximity.bio/</team>)\\n## Are you a Proximity pioneer?\\nWork alongside a world-class team of proximity medicine scientists to end “undruggables”\\n[Join Us](https://www.generalproximity.bio/<#>)[Join Us](https://www.generalproximity.bio/</careers>)\\n##### Newsletter\\n[Subscribe](https://www.generalproximity.bio/<https:/generalproximity.substack.com/>)[Subscribe](https://www.generalproximity.bio/<https:/generalproximity.substack.com/>)\\n##### Newsletter\\nThanks for subscribing! ✔️\\nPlease double-check the email.\\n[![General Proximity Logo](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6761c0d619a9810afc4ed7d2_gplogo.svg)](https://www.generalproximity.bio/</>)\\n  * [Team](https://www.generalproximity.bio/</team>)\\n  * [Careers](https://www.generalproximity.bio/</careers>)\\n  * [News](https://www.generalproximity.bio/</news>)\\n\\n\\nhello@generalproximity.bio\\n[](https://www.generalproximity.bio/<https:/www.linkedin.com/company/generalproximity/>)[](https://www.generalproximity.bio/<https:/x.com/proxbio>)\\n© 2024 General Proximity.\\n\" markdown_with_citations=\"![General Proximity Logo⟨1⟩](https://www.generalproximity.bio/</>)\\n  * Team⟨2⟩\\n  * Careers⟨3⟩\\n  * News⟨4⟩\\n\\n\\n![](https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67609cf8935161e8a93a2a78_hero-img.avif)\\n# Nothing\\nWe’re pioneering next-gen proximity medicines to redefine the future of medicine for all humankind.\\n# is\\n# Undruggable\\nWe’re pioneering next-gen proximity medicines to redefine the future of medicine for all humankind.\\n## Control Proximity,Control Biology\\nFirst Principles: All biological processes are driven by proximity. Why don’t our medicines work in the same way?\\n### general\\n[jen-rəl]\\nadjective\\nApplicable to all, unbiased\\nWe’ve built the first generalized, mechanism-agnostic, proximity discovery engine.Our genomes code for thousands of intricate molecular machines—effector proteins—which regulate all aspects of biology. These include chaperone, adaptor proteins, and trafficking proteins, all post-translational modification (PTM) readers/writers/erasers, and many others.In aggregate, these effector proteins comprise the ‘effectome’: the set of all proteins which modulate other proteins to control biology.To us they represent something even more: a boundless array of untapped biological tools.\\u200d\\n### proximity\\n[präk-si-mə-tē]\\nnoun\\nCloseness\\nProximity is a master regulator of biology. All biological processes are controlled through proximity on some level.Interactions or ‘proximity events’ between ‘target’ and ‘effector proteins’ can result in a vast constellation of downstream biology on a target protein—activation, refolding, re-localization, re-programming, functional modulation, degradation, etc. Manipulation of a given protein’s proximity topology thus enables nearly arbitrary control of that protein's function and biology.Our unbiased effector discovery platform allows us to discover the most powerful proximity mechanisms for a given target, enabling the development of highly-efficacious proximity therapeutics for targets previously beyond the reach of medicine.\\u200d\\u200d\\nPlay⟨5⟩Pause⟨5⟩\\nCollaborating with world-class institutions to create next gen proximity medicines\\n![⟨6⟩J&J](https://www.generalproximity.bio/<https:/www.jnj.com/>)![⟨7⟩UCSF](https://www.generalproximity.bio/<https:/www.ucsf.edu/>)![⟨8⟩Moffitt Cancer Center](https://www.generalproximity.bio/<https:/www.moffitt.org/>)![⟨9⟩JLabs](https://www.generalproximity.bio/<https:/enamine.net/>)\\nBacked by leading technical investors\\nHealthspan Capital![⟨10⟩](https://www.generalproximity.bio/<https:/www.healthspancapital.vc/>)Wilson Sonsini![⟨11⟩](https://www.generalproximity.bio/<https:/www.wsgr.com/en/services/practice-areas/corporate/emerging-companies.html>)![⟨12⟩Age1](https://www.generalproximity.bio/<https:/age1.com/>)Felisis Ventures![⟨13⟩](https://www.generalproximity.bio/<https:/www.felicis.com/>)Olive Capital![⟨14⟩.avif)](https://www.generalproximity.bio/<https:/www.olivevc.com/>)![⟨15⟩Modi Ventures](https://www.generalproximity.bio/<https:/www.modivc.com/>)![⟨16⟩Y Combinator](https://www.generalproximity.bio/<https:/www.ycombinator.com/>)\\nSupported by major grants\\nARPA H![⟨17⟩](https://www.generalproximity.bio/<https:/www.linkedin.com/feed/update/urn:li:activity:7255651295984771072/>)NCI![⟨18⟩](https://www.generalproximity.bio/<https:/www.cancer.gov/>)\\n![⟨19⟩MBC Biolabs](https://www.generalproximity.bio/<https:/mbcbiolabs.com/>)\\nAwarded a record number of big pharma “Golden Tickets”\\nServier![⟨20⟩](https://www.generalproximity.bio/<https:/servier.com/en/servier/>)Astellas![⟨21⟩](https://www.generalproximity.bio/<https:/www.astellas.com/en/>)Bristol Meyers Squib![⟨22⟩](https://www.generalproximity.bio/<https:/www.bms.com/>)Abbvie![⟨23⟩](https://www.generalproximity.bio/<https:/www.abbvie.com/>)Ono Pharma![Company Logo\\n⟨24⟩](https://www.generalproximity.bio/<https:/www.ono-pharma.com/en>)\\n## Our team is responsible for:\\n36+\\nFDA Approved Medicines\\n146\\nINDs\\n245\\nPatents\\n958\\nPublications\\nour team⟨5⟩our team⟨2⟩\\n## Are you a Proximity pioneer?\\nWork alongside a world-class team of proximity medicine scientists to end “undruggables”\\nJoin Us⟨5⟩Join Us⟨3⟩\\n##### Newsletter\\nSubscribe⟨25⟩Subscribe⟨25⟩\\n##### Newsletter\\nThanks for subscribing! ✔️\\nPlease double-check the email.\\n![General Proximity Logo⟨1⟩](https://www.generalproximity.bio/</>)\\n  * Team⟨2⟩\\n  * Careers⟨3⟩\\n  * News⟨4⟩\\n\\n\\nhello@generalproximity.bio\\n[](https://www.generalproximity.bio/<https:/www.linkedin.com/company/generalproximity/>)[](https://www.generalproximity.bio/<https:/x.com/proxbio>)\\n© 2024 General Proximity.\\n\" references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6761c0d619a9810afc4ed7d2_gplogo.svg: ![General Proximity Logo\\n⟨2⟩ https://www.generalproximity.bio/</team>: Team\\n⟨3⟩ https://www.generalproximity.bio/</careers>: Careers\\n⟨4⟩ https://www.generalproximity.bio/</news>: News\\n⟨5⟩ https://www.generalproximity.bio/<#>: Play\\n⟨6⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/676062518843c91f8458f2d8_jlabs.png: ![\\n⟨7⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f627dc9a3bad1b99d67_image%202685.avif: ![\\n⟨8⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/675a168d71b65c4bf3dc103c_moffitt-logo-full-white.svg: ![\\n⟨9⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f614da550fde650a759_elogo.avif: ![\\n⟨10⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f61995a0ea29ffc262c_image%202697.avif: Healthspan Capital![\\n⟨11⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f61d21f02b787f474a2_Wilson_Sonsini_Logo%201.avif: Wilson Sonsini![\\n⟨12⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f62f992eb0d2d7c55fc_age1logo.avif: ![\\n⟨13⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f62388a8321634e1c87_Frame%201538233611.avif: Felisis Ventures![\\n⟨14⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f627623048bcd522dc2_image%202692%20\\\\(Traced\\\\: Olive Capital![\\n⟨15⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f6280b07605dbfd034a_image%202691.avif: ![\\n⟨16⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f62c3e594b815519642_ycombinator-icon%201.avif: ![\\n⟨17⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6761b9be747e99faf31bc418_ARPA-H.svg: ARPA H![\\n⟨18⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6761bb7a85cd8c690946748e_NIH%20NCI.svg: NCI![\\n⟨19⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5f7d9edf61c7e54560_MBC-Biolabs-logo%20161.avif: ![\\n⟨20⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5f318f6d1da69fbb0b_servierlogo.avif: Servier![\\n⟨21⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5f6165b3f1a3914936_logo_white%201.avif: Astellas![\\n⟨22⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5f02963a4bfacaac70_Vector.png: Bristol Meyers Squib![\\n⟨23⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/67604f5fa650bf84c47baad9_AbbVie_logo%201.avif: Abbvie![\\n⟨24⟩ https://cdn.prod.website-files.com/6733cc83f163165c57c972df/6744a44686918e9eeec3ac4c_onologo.svg: Ono Pharma![Company Logo\\n\\n⟨25⟩ https://www.generalproximity.bio/<https:/generalproximity.substack.com/>: Subscribe\\n' fit_markdown='' fit_html=''",
  "generated_description": "### General Proximity: Revolutionizing Medicine Through Proximity\n\n**Company Overview:**\nGeneral Proximity, a forward-thinking biotech startup based in San Francisco, is taking on the challenge of drug discovery in a unique way. Founded during the Y Combinator W20 batch, this nimble team of around 15 is set on creating the next generation of induced-proximity medicines. Their vision is clear: redefine how we approach and develop therapeutics, making a meaningful impact on the future of medicine for everyone.\n\n**Mission:**\nThe core mission of General Proximity revolves around developing proximity medicines. According to them, proximity dictates biological processes — in their words, \"Control Proximity, Control Biology.\" Instead of following the conventional pathways of drug design, they aim to harness molecular interactions at close quarters to unlock new therapeutic potentials.\n\n**Technology and Approach:**\nThe company is pioneering what they call a \"generalized, mechanism-agnostic proximity discovery engine.\" This mechanism leverages the intricate network of effector proteins — these are the molecular machines that regulate biology at the most fundamental level. By mastering the interactions between target and effector proteins, General Proximity seeks to manipulate biological functions flexibly and effectively.\n\n**Collaborations:**\nGeneral Proximity has positioned itself alongside prestigious institutions like Johnson & Johnson, UCSF, and the Moffitt Cancer Center. These collaborations aim to accelerate the creation of next-gen proximity medicines, proving that the company is serious about tackling some of the toughest challenges in drug development.\n\n**Support and Growth:**\nThe company has received backing from prominent investors and strategic grants, including support from health-focused venture capital firms and entities like ARPA-H and the NCI. Their growing reputation is underscored by a record number of big pharma “Golden Tickets.” \n\n**Key Achievements:**\n- Over 36 FDA-approved medicines developed.\n- 146 Investigational New Drug Applications (INDs).\n- 245 patents awarded.\n- Nearly 1,000 scientific publications.\n\n**Join the Movement:**\nGeneral Proximity is on the lookout for talent. If you have a passion for innovation in medical science and want to be part of a team dedicated to overcoming the \"undruggables,\" they invite you to explore career opportunities.\n\n**In Summary:**\nGeneral Proximity is not just a biotech company; it’s a trailblazer in the making. By focusing on the fundamental science of proximity, they're designing the next generation of medicines that could change the landscape of healthcare. With a clear mission, a strong foundation in partnerships, and a commitment to innovation, they’re poised to make real waves in biomedicine. Check them out at [General Proximity](https://www.generalproximity.bio/). \n\nLet’s keep an eye on their journey. Who knows what breakthroughs might be on the horizon?"
}